VIGONVITA-B

Vigonvita Life Sciences staged a morning session comeback, climbing from an intraday low of HK$82.00 to HK$86.00 by 10:01 BJ time, up 3.80% amid prior heavy volatility. The rebound follows a previous single-day plunge of over 20% with no material negative catalyst, hinting at shifting speculative sentiment. Despite a PB of 29.51x and negative PE of -37.02x reflecting pre-profit status, the company recently won HKEX approval for full H-share circulation of 100.22 million shares, potentially improving free float. At HK$87.0, the stock remains 35.51% below its 52-week high of HK$134.9 but 70.59% above the 52-week low of HK$51.0, and trades above the 60-day MA (HK$73.735) yet below the 20-day MA (HK$96.48), portraying a mixed technical picture. While total market cap stands at ~HK$14.58 billion, turnover of just HK$684,780 suggests thin liquidity, capping the rally's conviction.

Shares of Vigonvita Life Sciences opened lower in the morning session, closing at HKD 83.2, down 5.6% from the previous close, with an intraday range of HKD 84.5 to 83.2 on thin volume of just 220,000 shares. The stock has retreated significantly from its 52-week high of HKD 134.9 on February 24, following the H-share full circulation approval and related news. It is now 38.3% below the 52-week high and has fallen below the 20-day moving average (HKD 96.6), though it remains above the 60-day moving average (HKD 73.7). With a price-to-book ratio of 28.2x and a negative P/E of -35.4x, valuation pressure persists amid heightened capital flows. Recent trading has been lackluster, with no notable buying support during the session. The company's pipeline of pipeline products, including those in neuropsychiatry and reproductive health, has previously attracted interest, but near-term moves remain sentiment-driven.

Vigonvita Life Sciences opened the morning session at its intraday high of HKD 92.6 before plunging to HKD 88.0, closing at the session low with a 5.02% decline on a meager turnover of HKD 525,230. The sharp drop appeared driven by heightened momentum trading, as no material negative catalysts emerged following recent positive developments including HKEX approval for full H-share circulation (involving ~100 million shares) and revenue coverage of interest expenses. At HKD 88, the stock trades 34.77% below its 52-week high of HKD 134.9, yet retains a 4.7% YTD gain and remains above its 60-day moving average of HKD 73.629, suggesting the medium-term uptrend is not fully broken. However, the trailing P/E of -37.45x and extreme P/B of 29.85x highlight stretched valuations, while the price has fallen below the 20-day MA of HKD 96.343, signaling short-term technical deterioration.

2630.HK surged 5.98% in the morning session, opening at HK$93.0 and quickly rising to HK$97.4, driven by the completion of its H-share full circulation approved by HKEX, which enhanced share liquidity. The company had earlier received CSRC filing for the full circulation of 100,220,667 H-shares, boosting free float. The current price of HK$97.4 is 27.8% below the 52-week high of HK$134.9, yet above the 20-day MA of HK$95.51 and 60-day MA of HK$73.53, with a YTD gain of 15.88%. However, the company remains loss-making with a P/E of -41.45x, indicating fundamental challenges persist.

2630.HK surged and then retreated sharply in the morning session, hitting an intraday high of 100.0 HK dollars before plunging to close at 91.0 HK dollars, down 5.55% from the previous close of 96.35 HK dollars, nearly erasing all intraday gains. The decline was driven by news that the company recently completed the full circulation of 100.22 million H shares, adding dilution overhang, alongside a management reshuffle appointing Tian Guanghui as general manager. With a price-to-book ratio of 30.87x and negative earnings per share, the valuation remains stretched. The stock has gained 8.27% year-to-date but still sits 32.54% below its 52-week high of 134.9 HK dollars and below the MA20 of 93.2 HK dollars, indicating technical weakness. However, with only 9,600 shares traded and a turnover rate of 0.01%, the low liquidity may have amplified the move.